1. Home
  2. MRBK vs IVA Comparison

MRBK vs IVA Comparison

Compare MRBK & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRBK
  • IVA
  • Stock Information
  • Founded
  • MRBK 2004
  • IVA 2011
  • Country
  • MRBK United States
  • IVA France
  • Employees
  • MRBK N/A
  • IVA N/A
  • Industry
  • MRBK Major Banks
  • IVA Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRBK Finance
  • IVA Health Care
  • Exchange
  • MRBK Nasdaq
  • IVA Nasdaq
  • Market Cap
  • MRBK 145.8M
  • IVA 359.6M
  • IPO Year
  • MRBK 2017
  • IVA 2020
  • Fundamental
  • Price
  • MRBK $13.67
  • IVA $3.09
  • Analyst Decision
  • MRBK Buy
  • IVA Strong Buy
  • Analyst Count
  • MRBK 2
  • IVA 4
  • Target Price
  • MRBK $17.00
  • IVA $10.50
  • AVG Volume (30 Days)
  • MRBK 102.7K
  • IVA 29.4K
  • Earning Date
  • MRBK 07-25-2025
  • IVA 03-26-2025
  • Dividend Yield
  • MRBK 3.88%
  • IVA N/A
  • EPS Growth
  • MRBK 33.85
  • IVA N/A
  • EPS
  • MRBK 1.42
  • IVA N/A
  • Revenue
  • MRBK $101,096,000.00
  • IVA $14,591,573.00
  • Revenue This Year
  • MRBK $20.44
  • IVA $15.38
  • Revenue Next Year
  • MRBK $10.56
  • IVA $24.22
  • P/E Ratio
  • MRBK $9.10
  • IVA N/A
  • Revenue Growth
  • MRBK 8.82
  • IVA N/A
  • 52 Week Low
  • MRBK $10.04
  • IVA $1.53
  • 52 Week High
  • MRBK $17.33
  • IVA $4.05
  • Technical
  • Relative Strength Index (RSI)
  • MRBK 52.20
  • IVA 41.87
  • Support Level
  • MRBK $11.16
  • IVA $3.00
  • Resistance Level
  • MRBK $13.11
  • IVA $3.40
  • Average True Range (ATR)
  • MRBK 0.50
  • IVA 0.20
  • MACD
  • MRBK 0.11
  • IVA -0.04
  • Stochastic Oscillator
  • MRBK 77.00
  • IVA 12.28

About MRBK Meridian Corporation

Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Share on Social Networks: